Te application of ex utero intrapartum treatment (EXIT) procedure for cardiothoracic disorders by SHI-MIN YUAN
14   |  SIGNA VITAE
The application of ex utero intrapartum treatment 
(EXIT) procedure for cardiothoracic disorders
SHI-MIN YUAN
Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian 
Medical University, Putian, Fujian Province, People’s Republic of China
Corresponding author:
Shi-Min Yuan
Department of Cardiothoracic Surgery
The First Hospital of Putian
389 Longdejing Street, Chengxiang District
Putian 351100, Fujian Province, People's Republic of China
E-mail: shi_min_yuan@yahoo.com
ABSTRACT
The ex utero intrapartum treatment 
(EXIT) procedure was primarily devel-
oped to reverse temporary tracheal occlu-
sion in patients with fetal surgery for con-
genital diaphragmatic hernia. Nowadays, it 
is widely used to resect fetal neck masses 
and to maintain an unobstructed airway. It 
is indicated for the management of several 
cardiothoracic diseases, including medi-
astinal or lung mass resection, drainage 
of pleural effusions, palliative treatment 
of critical congenital heart disease and 
establishment of EXIT-to-extracorporeal 
membrane oxygenation (ECMO). EXIT 
has been attempted successfully in many 
centers, and it has been proven that moth-
ers and babies tolerate the procedure well. 
Maternal and fetal surveillance during an-
esthesia is important to maintain maternal 
blood pressure and placental blood flow 
and fetal oxygenation. The aim of this arti-
cle is to discuss the application of the EXIT 
procedure for the management of fetal car-
diothoracic diseases.




The ex utero intrapartum treatment 
(EXIT) procedure was primarily devel-
oped to  reverse temporary tracheal occlu-
sion in patients undergoing fetal surgery 
for congenital diaphragmatic hernia. (1) 
The EXIT procedure requires an experi-
enced multi-disciplinary team that may in-
clude pediatric surgeons, an obstetrician, 
neonatologist, anesthesiologist and scrub 
nurses. The anesthesiologist is crucial for 
maintaining uteroplacental perfusion and 
maternal arterial pressure and muscle re-
laxation. Fetal analgesia and paralysis are 
ensured with vecuronium, fentanyl and 
atropine before hysterectomy or immedi-
ately after fetal exposure. Cooperation be-
tween pediatric surgeons and anesthetists 
is anticipated for preventing uterine atony 
and excessive maternal bleeding. (2)
The EXIT procedure allows therapeutic in-
terventions on the neonate while maintain-
ing fetoplacental circulation and thereby 
maintaining oxygenation. The EXIT pro-
cedure was primarily established as a safe 
technique initially designed for reversal of 
tracheal obstruction in a fetus with severe 
congenital diaphragmatic hernia. Nowa-
days, it is widely used to resect fetal neck 
masses and to maintain an unobstructed 
airway. (3) Liechty et al. (3) reported that 
the mean duration of EXIT was 28 ± 22 
minutes during intrapartum airway man-
agement for giant fetal neck masses. At 
present, the EXIT procedure has been 
extended to fetal anomalies where resus-
citation may be compromised, including 
large thoracic masses, severe congenital 
diaphragmatic hernia, or pulmonary agen-
esis. (4) The use of the EXIT procedure in 
fetuses for cardiothoracic diseases has not 
been fully elaborated. This article will dis-
cuss the application of the EXIT procedure 
in fetal cardiothoracic diseases.
MEDIASTINAL TUMORS
Fetal mediastinal teratomas can cause in-
trathoracic compression and non-immune 
hydrops fetalis, and neonatal respiratory 
distress. Mediastinal teratomas are usually 
detected on routine ultrasound during 2nd 
and 3rd trimester. In 2005, Merchant et al. 
(5) reported their experiences in managing 
a fetal mediastinal teratoma in 2 cases. One 
was successfully resected by fetal open sur-
gery at 23-week gestation, and the other, 
using the EXIT procedure for establish-
ment of an airway and tumor resection on 
uteroplacental support. They defined that 
a fetus <30-week gestation with a massive 
mediastinal teratoma and hydrops fetalis 
was an indication for open fetal surgery, 
while that >30-week gestation warranted 
an EXIT procedure. Recently, Agarwal et 
al. (6) reported a fetus with a large medi-
astinal teratoma, with large pericardial ef-
fusions and non-immune hydrops fetalis, 
that was successfully managed with peri-
cardiocentesis and surgical resection of the 
large teratoma using the EXIT procedure. 
One of the cases of fetal intrapericardial 
teratomas that were managed by Rychik et 
al. (7) was by EXIT procedure at 31 weeks, 
and the tumor was successfully resected 
while on placental support.
LUNG MASSES
The EXIT procedure is preferred for near-
term fetuses with large lung masses and 
mediastinal compression. Cass et al. (8) 
reported 9 fetuses with large lung masses, 
causing persistent mediastinal compres-
sion that received EXIT procedures. All 
procedures were successful without fetal 
or maternal operative complications. The 
fetal operative time (uteroplacental bypass 
time) was 43.2 ± 21.8 min, and the mater-
nal operative time was 136.1 ± 15.0 min. 
Comparisons between fetuses undergoing 
the EXIT procedure and standard delivery 
revealed no intergroup difference in peri-
natal conditions, including survival (EXIT, 
100% vs. Standard delivery, 71%, p = 0.18). 
Bouchard et al. (2) reported a fetus with 
a large cystic lung lesion, evaluated at 26- 
and 36-week gestation, and it was noted 
that the mass had a constant size. The fetus 
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was diagnosed with congenital cystic ade-
nomatoid malformation (CCAM), with no 
evidence of hydrops fetalis. An EXIT pro-
cedure was planned considering the pos-
sible difficulty of ventilation at birth. After 
hysterotomy, the fetal head was delivered 
and the baby intubated. The mass was re-
sected on placental bypass which lasted 66 
minutes. (2)
CONGENITAL CARDIAC ANOMALIES
Some congenital cardiac anomalies be-
come progressively severe during preg-
nancy . An in utero procedure can success-
fully prevent or minimize the progression 
in some cases, particularly for those fetuses 
evolving into hypoplastic left heart syn-
drome. A second choice for improving fe-
tal outcome is the EXIT procedure, which 
can be performed safely by controlling the 
airway in fetuses with airway obstruction 
or intrathoracic compression due to mass-
es. (9)
ESOPHAGEAL ATRESIA AND STEN-
OTIC BRONCHUS REPAIR
Bouchard et al. (2) reported a fetus diag-
nosed on ultrasound at 19 weeks’ gesta-
tion with unilateral pulmonary agenesis, 
polyhydramnios and suspected esophageal 
atresia. An EXIT procedure was carried 
out on the baby for esophageal atresia re-
pair and rib graft reconstruction of a sten-
otic bronchus to the solitary lung.
EXIT-TO-ECMO
Extracorporeal membrane oxygenation 
(ECMO) can be used if an airway cannot 
be established, if the fetus and its placental 
support become unstable, or if the lungs 
cannot support the patient during the 
initial neonatal period. EXIT-to-ECMO 
facilitates airway control, arterial and ve-
nous cannula insertion for ECMO while 
on placental support for fetuses with se-
vere pulmonary or cardiac malformations. 
Bouchard et al. (2) reported, in a fetus with 
a left congenital diaphragmatic hernia 
and a tetralogy of Fallot, EXIT-to-ECMO 
which was performed at 36-weeks gesta-
tion.ECMO was established by cannulat-
ing the internal carotid artery and internal 
jugular vein, while on uteroplacental sup-
port for 90 minutes. The EXIT procedure 
is also useful for fetuses separated from the 
uteroplacental circulation, with immediate 
instability of the neonate. In such cases, the 
EXIT procedure avoids hypoxia or acido-
sis during neonatal resuscitation. Marwan 
and Crombleholme (10) also offered EX-
IT-to-ECMO for fetuses with severe aortic 
stenosis or hypoplastic left heart syndrome 
associated with a restrictive atrial septum. 
EXIT-to-ECMO was applied with the op-
tion of traditional cardiopulmonary by-
pass (CPB) with an open reservoir as the 
baby was delivered and transferred to a 
separate operating room. Matte et al. (11) 
made use of the A Modified EXIT-To-EC-
MO with Optional Reservoir (METEOR) 
circuit to commence ECMO support with 
a traditional CPB by aorta-right atrium 
cannulation with an open reservoir and 
cardiotomy suction. ECMO support was 
initiated at 250 mL/min (100 mL/kg), the 
umbilical cord was clamped and the baby 
was fully delivered.
PERICARDIAL EFFUSIONS
Management of isolated pericardial effu-
sion depends on the severity of the effu-
sion and associated development of fetal 
distress or cardiac insufficiency as mani-
fested by hydrops fetalis. Fetal hydrotho-
rax is usually managed either in utero by 
thoracocentesis, thoracoamniotic shunt or 
postnatally by immediate intubation and 
thoracocentesis (12,13) and rarely by EXIT 
procedure (5), in order to prolong preg-
nancy and allow better lung development. 
It has been proven that EXIT supported 
thoracocentesis is of lowest risk with tem-
porary preservation of the fetoplacental 
circulation allowing unhurried drainage 
of the thoracic cavities for lung expansion 
before birth. (14) Bouchard et al. (2) re-
ported a 31-week gestation fetus with bi-
lateral congenital cystic adenomatoid mal-
formation associated with massive ascites, 
diagnosed by fetal ultrasound. The EXIT 
procedure was performed to relieve severe 
hydrops fetalis. After hysterotomy, prior to 
delivery of the baby, massive fetal ascites 
were removed. Complete atresia warranted 
fetal surgical tracheostomy. The uteropla-
cental bypass time was 25 minutes. (2)
The antenatal approach may not always be 
feasible due to an unacceptable risk as a 
result of fetal and placental position. Post-
natal intubation and thoracocentesis may 
expose the neonate to permanent hypox-
emic brain damage when thoracocentesis 
and further lung expansion for alveolar gas 
exchange fail. Henry et al. (15) revealed 
the important aspects of EXIT procedure 
used in management of hydrops fetalis: 
The mean time of detection was 27.3 ±5.6 
weeks of gestation: 75% were detected dur-
ing the third trimester, while a few cases 
were detected as early as 13-week gesta-
tion. The course varied from spontaneous 
resolution (22%) to favorable outcome 
after treatment (43%) and poor outcome 
(fetal/neonatal death) (35%). Those with 
unilateral pleural effusion, with no poly-
hydramnios or hydrops fetalis, were more 
likely to have spontaneous resolution. Hy-
drops was a risk factor of poor outcome, 
irrespective of bilateral effusions and ges-
tational age at delivery. Therapeutic proce-
dures like bronchoscopy, surfactant instil-
lation, tracheotomy and tracheoplasty can 
be performed with the aid of the EXIT pro-
cedure by allowing establishment of airway 
via endotracheal intubation or by trache-
ostomy. The EXIT procedure for primary 
fetal hydrothorax took only 5-8 minutes. 
A longer duration of the EXIT procedure 
brought about difficulty for the anesthesi-
ologist to maintain uteroplacental circula-
tion and to keep the uterus relaxed.
Henry et al. (15) reported the EXIT pro-
cedure in 2 cases of fetuses with bilateral 
pleural effusion or poly-hydramnios, with-
out hydrops fetalis or heart anomalies 
at 38-weeks gestation. Postnatal X-ray 
showed no evidence of plural effusion and 
normal lung parenchyma. Prontera et al. 
(16) reported a moderately macrosomic fe-
tus with severe polyhydramnios, with iso-
lated bilateral pleural effusions and with no 
cardiac malformations, in which an EXIT 
procedure was performed successfully at 
38-week gestation. They suggested that the 
right hemithorax be drained first to mini-
mize compression of the central veins by 
the opposite side.
By using EXIT, adequate ventilation can be 
achieved during the procedure with an ex-
pected excellent outcome. (5) Mothers and 
babies tolerated the EXIT procedure well, 
when the fetuses were in their 29-40-week 
gestition, without signs of fetal hemody-
namic instability. (2) By comparison, ma-
ternal blood loss during the EXIT proce-
dure was 848 mL, which was compatable 
to conventional cesarean section. (2) There 
might be 2 concerns of maternal anesthe-
sia: 1) left uterine displacement for avoid-
ing maternal hypotension and maintaining 
adequate maternal cardiac output, and 2) 
caution of volatile anesthetics for prevent-
ing decreases in maternal blood pressure 
and myometrial tone and decrease in fetal 
oxygenation. (10) Intrapartum complica-
tions in mothers occurred in 10% of cases 
and included hemorrhage, uterine atony, 
placental abruption, and dehiscence of a 
prior uterine scar. (17)
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CONCLUSIONS
The EXIT is a safe procedure under ad-
equate fetal ventilation and uteroplacental 
circulation support. It is indicated for the 
management of several cardiothoracic dis-
eases, including mediastinal or lung mass 
resection, drainage of pleural effusions, 
palliative treatment of critical congenital 
heart disease and establishment of EXIT-
to-ECMO. EXIT has been attempted suc-
cessfully in many centers, and it has been 
proven that mothers and babies tolerate 
the procedure well. Maternal and fetal sur-
veillance during anesthesia is important 
to maintain maternal blood pressure and 
placental blood flow and fetal oxygenation.
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